NEW YORK, NY / ACCESSWIRE / April 24, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)
Class Period: August 4, 2016 to January 31, 2019
Lead Plaintiff Deadline: April 26, 2019

The complaint alleges that throughout the class period AVEO Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO’s lead candidate drug, tivozanib, from the TIVO-1 trial presented in June 2013; (ii) tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; (iii) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (iv) as a result, AVEO’s public statements were materially false and misleading at all relevant times.

Get additional information about the AVEO lawsuit: http://www.kleinstocklaw.com/pslra-1/aveo-pharmaceuticals-inc-loss-submission-form?id=1251&from=1.

Inogen, Inc. (NASDAQGS: INGN)
Class Period: November 8, 2017 to February 26, 2019
Lead Plaintiff Deadline: May 6, 2019

Throughout the class period, Inogen, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Inogen had overstated the true size of the total addressable market (“TAM”) for its portable oxygen concentrators and had misstated the basis for its calculation of the TAM; (ii) Inogen had falsely attributed its sales growth to the strong sales acumen of its salesforce, when in reality it was due in large part to sales tactics designed to deceive its elderly customer base; (iii) the growth in Inogen’s domestic business-to-business sales to home medical equipment (“HME”) providers was inflated, unsustainable and was eroding direct-to-consumer sales; and (iv) very little of Inogen’s business was actually coming from the more stable Medicare market.

Get additional information about the INGN lawsuit: http://www.kleinstocklaw.com/pslra-1/inogen-inc-loss-submission-form?id=1251&from=1.

Nutanix, Inc. (NASDAQGS: NTNX)
Class Period: Class A shares purchased between March 2, 2018 and February 28, 2019
Lead Plaintiff Deadline: May 28, 2019

The complaint concerns whether the Company and its executives violated federal securities laws by making false and/or misleading statements about its investments in growth and its maintenance of high profit margins.

On February 28, 2019, Nutanix announced its second quarter fiscal 2019 results and reported third quarter guidance that was below analysts’ expectations. Management acknowledged that “inadequate marketing spend for pipeline generation and slower than expected sales hiring” were the reasons for the weak guidance. On this news, Nutanix’s share price fell from $50.09 per share on February 28, 2019 to a closing price of $33.70 on March 1, 2019.

Get additional information about the NTNX lawsuit: http://www.kleinstocklaw.com/pslra-1/nutanix-inc-loss-submission-form?id=1251&from=1.

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm